CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade BioMarin Pharmaceutical Inc - BMRN CFD

62.94
3.02%
Market Trading Hours* (UTC) Opens on Wednesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.31
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024318 %
Charges from full value of position ($-4.62)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024318%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002096 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002096%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 64.9
Open 64.85
1-Year Change -29.72%
Day's Range 62.94 - 64.85
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 3, 2024 62.94 -1.72 -2.66% 64.66 64.86 62.93
Dec 2, 2024 64.90 -0.57 -0.87% 65.47 65.76 64.79
Nov 29, 2024 65.78 1.02 1.58% 64.76 66.08 64.76
Nov 27, 2024 65.24 0.76 1.18% 64.48 65.45 64.38
Nov 26, 2024 64.77 0.17 0.26% 64.60 64.96 63.96
Nov 25, 2024 64.79 0.59 0.92% 64.20 65.60 63.83
Nov 22, 2024 64.17 0.65 1.02% 63.52 64.39 63.52
Nov 21, 2024 63.34 1.80 2.92% 61.54 63.66 61.15
Nov 20, 2024 62.52 1.19 1.94% 61.33 62.63 61.00
Nov 19, 2024 61.74 0.31 0.50% 61.43 61.95 60.79
Nov 18, 2024 61.89 -1.03 -1.64% 62.92 63.37 61.30
Nov 15, 2024 63.32 -2.23 -3.40% 65.55 65.60 63.11
Nov 14, 2024 65.54 -0.33 -0.50% 65.87 66.90 65.35
Nov 13, 2024 66.57 0.62 0.94% 65.95 66.92 65.72
Nov 12, 2024 66.07 0.70 1.07% 65.37 66.62 65.37
Nov 11, 2024 66.28 -0.03 -0.05% 66.31 67.84 66.11
Nov 8, 2024 67.00 0.74 1.12% 66.26 67.36 66.26
Nov 7, 2024 66.86 0.81 1.23% 66.05 67.24 65.40
Nov 6, 2024 66.06 -1.20 -1.78% 67.26 67.26 65.69
Nov 5, 2024 65.95 0.19 0.29% 65.76 66.16 65.27

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BioMarin Company profile

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioMarin Pharmaceutical Inc. revenues decreased 1% to $1.85B. Net loss before extraordinary items totaled $68M vs. income of $4.6M. Revenues reflect Kuvan1 segment decrease of 38% to $285.8M, Naglazyme1 segment decrease of 3% to $380.4M, United States segment decrease of 28% to $657.7M, Latin America segment decrease of 7% to $191.2M.

Equity composition

Common Stock $.001 Par, 04/11, 250M auth., 110,909,591 issd. Insiders own 0.26%. IPO 7/23/99, 4.5M shs. $13 by U.S. Bancorp Piper Jaffray. PO 12/01, 8,050,000 shs. @ $12 by UBS Warburg. 5/01, private placement 4,763,712 shares @ $9.45. PO 2/03, 7.5M shs @ $10 by UBS Warburg. PO 3/06 10,350,000 shs. @ $13/sh.

Industry: Biopharmaceuticals

105 Digital Dr
NOVATO
CALIFORNIA 94949
US

News

Tesla’s logo on a building

Tesla (TSLA) stock forecast: third-party Tesla price target

Where will Tesla’s stock be in five years? Can the EV company keep its crown?

09:32, 4 December 2024
Silver coins and bullion

Silver price forecast 2025 and beyond: Third party price target

Rising interest rates and a strong dollar pushed silver to a two-year last September, but what lies ahead?

16:00, 3 December 2024
SHIB cryptocurrency logo, showing a cartoon Shiba Inu dog on a coin, over a golden orange background with circuit board graphics detail

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

16:41, 28 November 2024
Gold bars on a black background with a diagram

Gold price predictions for the next five years: Third party data round up

Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.

15:17, 18 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

People also watch

Oil - Crude

69.88 Price
-0.160% 1D Chg, %
Long position overnight fee 0.0036%
Short position overnight fee -0.0255%
Overnight fee time 22:00 (UTC)
Spread 0.040

BTC/USD

96,061.80 Price
-0.160% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,642.88 Price
+0.030% 1D Chg, %
Long position overnight fee -0.0170%
Short position overnight fee 0.0088%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

2.58 Price
-2.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01285

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading